Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Neuromodulation and Cognitive Training for Substance Use Disorders

Lead Sponsor:

University of Minnesota

Conditions:

Stimulant Use

Alcohol Use Disorder

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interv...

Detailed Description

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interv...

Eligibility Criteria

Inclusion

  • Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment
  • Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.
  • Able to provide written consent and comply with study procedures.
  • Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).

Exclusion

  • Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)
  • Over 9 months of abstinence from substance use
  • A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
  • Presence of a condition that would render study measures difficult or impossible to administer or interpret
  • Age outside the range of 18 to 65
  • Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except for caffeine or nicotine (Nicotine use will be recorded but is not exclusionary)
  • Entrance to the treatment program under a court mandate. (i.e. legally incarcerated)
  • History of ECT or cortical energy exposure within the past 6 months, including participation in any other neuromodulation studies

Key Trial Info

Start Date :

July 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2026

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT04426214

Start Date

July 16 2021

End Date

September 1 2026

Last Update

August 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Minnesota Fairview

Minneapolis, Minnesota, United States, 55454